Financial Performance - The company's operating revenue for 2022 was ¥187,873,774.49, a decrease of 4.22% compared to the previous year[3] - The net profit attributable to shareholders was ¥23,423,999.31, down 3.38% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,621,322.98, a decline of 9.84% compared to the previous year[5] - Basic earnings per share were ¥0.34, reflecting a decrease of 2.86% year-on-year[5] - The decline in revenue and net profit was primarily due to the impact of the pandemic on customer demand and operational activities[6] Assets and Equity - Total assets at the end of the reporting period were ¥441,281,442.83, an increase of 22.49% from the beginning of the period[5] - Shareholders' equity attributable to the company increased by 48.02% to ¥296,071,255.92 compared to the beginning of the period[5] - The company's net asset value per share rose to ¥3.54, a growth of 21.23% from the start of the period[4] - The increase in total assets and equity was attributed to the public issuance of shares and the increase in retained earnings[7] Cautionary Notes - Investors are advised to exercise caution as the financial data presented is preliminary and unaudited[8]
辰光医疗(430300) - 2022 Q4 - 年度业绩